Biota Pharmaceuticals to Present at the 2015 BIO CEO & Investor Conference

ATLANTA, Feb. 3, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"), a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening viral respiratory infectious diseases, announced today that Biota CEO & President Joseph Patti will present a corporate overview at the 2015 BIO CEO & Investor Conference. The presentation will take place on Tuesday, February 10, 2015 at 3:00 p.m. EST at the Waldorf Astoria Hotel in New York, NY.

A live webcast of the presentation can be accessed under "Events and Presentations" in the Investors section of the Company's website at www.biotapharma.com or at http://www.veracast.com/webcasts/bio/ceoinvestor2015/91221174867.cfm. A replay of the webcast will be archived for 30 days following the presentation.

About Biota Pharmaceuticals, Inc.

Biota Pharmaceuticals, Inc. is a company focused on the discovery and development of products to treat serious viral respiratory infectious diseases. The Company currently has two clinical-stage Phase 2 product candidates: (i) laninamivir octanoate, which is being developed as a one-time treatment for influenza A and B infections; and (ii) vapendavir, a potent, broad spectrum capsid inhibitor of enteroviruses in development for the treatment of human rhinovirus infected patients with underlying respiratory illnesses, such as moderate-to-severe asthma and chronic obstructive pulmonary disease (COPD). The Company is also conducting IND-enabling studies with BTA-C585, an orally bioavailable F protein inhibitor, in development for the treatment of respiratory syncytial virus infections. For additional information about the Company, please visit www.biotapharma.com.

Biota is a registered trademark of Biota Pharmaceuticals, Inc.

CONTACT: Joseph M. Patti, PhD President and Chief Executive Officer (678) 221-3351 j.patti@biotapharma.com Sarah McCabe Stern Investor Relations, Inc. (267) 909-9237 sarah@sternir.com

Source:Biota Pharmaceuticals, Inc.

More From Press Releases